Biocon Ltd
NSE:BIOCON

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
NSE:BIOCON
Watchlist
Price: 331.5 INR 2.6% Market Closed
Market Cap: 398B INR
Have any thoughts about
Biocon Ltd?
Write Note

Biocon Ltd
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biocon Ltd
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Biocon Ltd
NSE:BIOCON
Intangible Assets
â‚ą102.9B
CAGR 3-Years
103%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Intangible Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Transgene Biotek Ltd
BSE:526139
Intangible Assets
â‚ą65.5m
CAGR 3-Years
-32%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Intangible Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hester Biosciences Ltd
NSE:HESTERBIO
Intangible Assets
â‚ą39.9m
CAGR 3-Years
126%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Panacea Biotec Ltd
NSE:PANACEABIO
Intangible Assets
â‚ą360m
CAGR 3-Years
33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biocon Ltd
Glance View

Market Cap
398B INR
Industry
Biotechnology

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,203 full-time employees. The company went IPO on 2004-04-17. The firm is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.

BIOCON Intrinsic Value
455.48 INR
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Biocon Ltd's Intangible Assets?
Intangible Assets
102.9B INR

Based on the financial report for Sep 30, 2024, Biocon Ltd's Intangible Assets amounts to 102.9B INR.

What is Biocon Ltd's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
60%

Over the last year, the Intangible Assets growth was -3%. The average annual Intangible Assets growth rates for Biocon Ltd have been 103% over the past three years , 60% over the past five years .

Back to Top